Evaluation of the Serum Dkk-1, Tenascin-C, Oxidative Stress Markers Levels and Wnt Signaling Pathway Genes Expression in Patients with Alzheimer’s Disease

Hasanzadeh, Zahra; Nourazarian, Alireza; Nikanfar, Masoud; Laghousi, Delara; Vatankhah, Amir Mansour; Sadrirad, Somayeh

doi:10.1007/s12031-020-01710-9

Cited by 9 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But similar to the situation in tissues, increased TN-C levels in serum are also found in additional pathologies. Some of the conditions known to have increased serum TN-C levels include spondylitis, sepsis, myocardial defects, traumatic brain injuries, rheumatic diseases, pulmonary hypertension, Alzheimer's disease, systemic lupus, idiopathic inflammatory myositis, muscular dystrophy, chronic hepatitis C infection, and chronic renal diseases (139)(140)(141)(142)(143)(144)(145)(146). Common to most of these conditions is the fact that they involve an inflammatory reaction.…”

Section: Diagnostic And/or Prognostic Tumor Biomarkermentioning

confidence: 99%

Revisiting the Tenascins: Exploitable as Cancer Targets?

Tucker

Degen

2022

Front. Oncol.

View full text Add to dashboard Cite

For their full manifestation, tumors require support from the surrounding tumor microenvironment (TME), which includes a specific extracellular matrix (ECM), vasculature, and a variety of non-malignant host cells. Together, these components form a tumor-permissive niche that significantly differs from physiological conditions. While the TME helps to promote tumor progression, its special composition also provides potential targets for anti-cancer therapy. Targeting tumor-specific ECM molecules and stromal cells or disrupting aberrant mesenchyme-cancer communications might normalize the TME and improve cancer treatment outcome. The tenascins are a family of large, multifunctional extracellular glycoproteins consisting of four members. Although each have been described to be expressed in the ECM surrounding cancer cells, tenascin-C and tenascin-W are currently the most promising candidates for exploitability and clinical use as they are highly expressed in various tumor stroma with relatively low abundance in healthy tissues. Here, we review what is known about expression of all four tenascin family members in tumors, followed by a more thorough discussion on tenascin-C and tenascin-W focusing on their oncogenic functions and their potential as diagnostic and/or targetable molecules for anti-cancer treatment purposes.

show abstract